AbbVie Inc. EVP and Chief Operations Officer Azita Saleki filed a Form 4 on November 18, 2026, disclosing a stock option exercise and same-day share disposition in AbbVie common stock on November 16, 2026.
Key Highlights
- Option exercise: Saleki acquired 23,935 shares of AbbVie common stock via an option exercise (transaction code M) at $61.36 per share on November 16, 2026.
- Shares disposed: 13,481 shares were disposed of (transaction code F) at a weighted average price of $298.55, with individual transaction prices ranging from $298.55 to $298.64.
- Direct ownership after transactions: Saleki directly held 208,248 shares of common stock following the reported transactions.
- Indirect holdings: An additional 2,764 shares are held indirectly through an AbbVie Savings program profit sharing trust, including shares acquired via a dividend reinvestment feature, as of November 16, 2026.
- Underlying option: The exercised option was granted under the AbbVie Amended and Restated 2013 Incentive Stock Program, with 23,935 derivative securities remaining beneficially owned following the transaction.
Saleki Option Exercise and Share Disposition Details - November 2026
According to the Form 4 filed with the SEC on November 18, 2026, Azita Saleki, EVP and Chief Operations Officer of AbbVie Inc. (NYSE:ABBV), reported two transactions in the company's common stock ($0.01 par value) on November 16, 2026. First, Saleki exercised a stock option (transaction code M), acquiring 23,935 shares at a conversion price of $61.36 per share, bringing her directly held total to 221,729 shares at that point.
Immediately following the exercise, 13,481 shares were disposed of under transaction code F at a weighted average price of $298.55. The filing notes that these shares were sold in multiple transactions at prices ranging from $298.55 to $298.64, inclusive, and that full details on the number of shares sold at each individual price within that range are available upon request to AbbVie, any security holder, or the SEC staff. After this disposal, Saleki's direct beneficial ownership stood at 208,248 shares, the filing disclosed.
The exercised option was identified in Table II as an employee stock option granted under the AbbVie Amended and Restated 2013 Incentive Stock Program, described as "a transaction exempt from Section 16 under Rule 16b-3." According to the filing, that option became exercisable in annual increments of 15,957 shares on February 16, 2018, 15,956 shares on February 16, 2019, and 15,957 shares on February 16, 2020, with an expiration date of February 15, 2027. Following the exercise of 13,481 options, 23,935 derivative securities remain directly beneficially owned, the filing stated. The Form 4 was signed by T.O. Odutayo as Attorney-in-Fact for Azita Saleki.
What Was Disclosed
The filing disclosed an option exercise and partial share disposal by AbbVie's EVP and Chief Operations Officer on November 16, 2026, resulting in direct beneficial ownership of 208,248 shares and indirect ownership of 2,764 shares through a profit sharing trust.



Please wait processing your request...